Acorda Common Stock Total Equity from 2010 to 2024
| ACOR Stock | USD 0.85 0.00 0.00% |
Common Stock Total Equity | First Reported 2003-09-30 | Previous Quarter 9 K | Current Value 11 K | Quarterly Volatility 4.8 M |
Check Acorda Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acorda main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.2 M, Interest Expense of 30 M or Selling General Administrative of 132.7 M, as well as many exotic indicators such as Price To Sales Ratio of 0.15, Dividend Yield of 0.0954 or Days Sales Outstanding of 50.99. Acorda financial statements analysis is a perfect complement when working with Acorda Therapeutics Valuation or Volatility modules.
Acorda | Common Stock Total Equity |
Pair Trading with Acorda Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acorda Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acorda Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Acorda Stock
| 0.68 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Acorda Stock
| 0.47 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
| 0.42 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
| 0.41 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Acorda Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acorda Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acorda Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acorda Therapeutics to buy it.
The correlation of Acorda Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acorda Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acorda Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acorda Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Acorda Stock analysis
When running Acorda Therapeutics' price analysis, check to measure Acorda Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acorda Therapeutics is operating at the current time. Most of Acorda Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acorda Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acorda Therapeutics' price. Additionally, you may evaluate how the addition of Acorda Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Acorda Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acorda Therapeutics. If investors know Acorda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acorda Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.873 | Earnings Share (203.57) | Revenue Per Share 94.713 | Quarterly Revenue Growth 0.207 | Return On Assets (0.06) |
The market value of Acorda Therapeutics is measured differently than its book value, which is the value of Acorda that is recorded on the company's balance sheet. Investors also form their own opinion of Acorda Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acorda Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acorda Therapeutics' market value can be influenced by many factors that don't directly affect Acorda Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acorda Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acorda Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acorda Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.